Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Renal cancer" to "[[Category:Renal_cell_carcinoma") |
||
Line 48: | Line 48: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
− | [[Category: | + | [[Category:Renal_cell_carcinoma medications]] |
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] |
Revision as of 12:54, 30 July 2018
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
- Hepatocellular carcinoma
- Non-small cell lung cancer
- Prostate cancer
- Renal cancer
- Medullary thyroid cancer
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 11/29/2012: FDA approved (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC).
- 4/25/2016: FDA approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
- 12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC).
Also known as
- Code names: XL184, XL-184
- Brand names: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)
Categories:
- Drugs
- Oral medications
- Kinase inhibitors
- AXL inhibitors
- FLT3 inhibitors
- KIT inhibitors
- MET inhibitors
- RET inhibitors
- ROS1 inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGFR inhibitors
- Hepatocellular carcinoma medications
- Non-small cell lung cancer medications
- Prostate cancer medications
- Renal cell carcinoma medications
- Thyroid cancer medications
- Drugs FDA approved in 2012